GlassScriptPhysician profile
Alan L Holton
NPI 1316938798
$1,199.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $57.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.89 | 2019-2020 | |
| Astellas Pharma US INC | $207.70 | 2019 | |
| Therapeuticsmd, INC. | $158.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.62 | 2019-2020 | |
| Novo Nordisk INC | $100.90 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.33 | 2019 | |
| Lupin INC. | $22.41 | 2019 | |
| Daiichi Sankyo INC. | $20.93 | 2019 | |
| Mayne Pharma Commercial LLC | $17.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.66 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.03 | 2019 | |
| Pfizer INC. | $13.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Holton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.